Harnessing mixed chimerism and programmed cell death protein 1/programmed death ligand 1 signaling for transplant tolerance

被引：0
|
作者：
Li, Shuang [2 ]
Zou, Dawei [1 ,3 ]
机构：
[1] Houston Methodist Res Inst, Dept Cardiovasc Sci, Houston, TX USA
[2] Houston Methodist Hosp, Houston Methodist Res Inst, Immunobiol & Transplant Sci Ctr, Dept Surg, Houston, TX USA
[3] Houston Methodist Hosp, Houston Methodist Res Inst, Immunobiol Transplant Sci Ctr, 6670 Bertner Ave,R7-430-3, Houston, TX 77030 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2024年 / 24卷 / 01期
关键词：
T cell; transplant tolerance; mixed chimerism; PD-1/PD-L1; T cell exhaustion; T cell anergy;
D O I：
10.1016/j.ajt.2023.09.016
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：147 / 148
页数：2
相关论文
共 50 条
  • [41] Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma
    Yokoyama, Shintaro
    Miyoshi, Hiroaki
    Nakashima, Kazutaka
    Shimono, Joji
    Hashiguchi, Toshihiro
    Mitsuoka, Masahiro
    Takamori, Shinzo
    Akagi, Yoshito
    Ohshima, Koichi
    CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4727 - 4734
  • [42] New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone
    Hu-Lieskovan, Siwen
    Ribas, Antoni
    CANCER JOURNAL, 2017, 23 (01): : 10 - 22
  • [43] Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma
    Cheah, Chan Yoon
    Fowler, Nathan H.
    Neelapu, Sattva S.
    CURRENT OPINION IN ONCOLOGY, 2015, 27 (05) : 384 - 391
  • [44] Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer
    Liang, Yuehua
    Liu, Xiaoran
    Li, Kun
    Li, Huiping
    CHINESE JOURNAL OF CANCER RESEARCH, 2022, 34 (02) : 117 - 130
  • [45] Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B
    Zhang, Wen-Jin
    Peng, Chuan-Hui
    Zheng, Shu-Sen
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2013, 12 (04) : 394 - 399
  • [46] Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer
    Yuehua Liang
    Xiaoran Liu
    Kun Li
    Huiping Li
    Chinese Journal of Cancer Research, 2022, 34 (02) : 117 - 130
  • [47] Distinct prognostic values of programmed death-ligand 1 and programmed cell death protein 1 in lung adenocarcinoma and squamous cell carcinoma patients
    Wang, Shuo
    Qu, Xiujuan
    Li, Zhi
    Che, Xiaofang
    Cao, Lili
    Yang, Xianghong
    Hu, Xuejun
    Xu, Ling
    Hou, Kezuo
    Fan, Yibo
    Wen, Ti
    Liu, Yunpeng
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (05)
  • [48] Positive clinical outcomes following therapy with programmed cell death protein 1/programmed cell death ligand 1 inhibitors in neuroendocrine carcinoma of the cervix
    Liu, Rongyu
    He, Xinlin
    Li, Zhengyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [49] Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
    Fan, Jingjing
    Shen, Xiangfeng
    Wang, Yishu
    Zhou, Hong-Lan
    Liu, Guolong
    Li, Yu-Lin
    Xu, Zhi-Xiang
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 130
  • [50] Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines
    Yamane, Hiromichi
    Isozaki, Hideko
    Takeyama, Masami
    Ochi, Nobuaki
    Kudo, Kenichiro
    Honda, Yoshihiro
    Yamagishi, Tomoko
    Kubo, Toshio
    Kiura, Katsuyuki
    Takigawa, Nagio
    AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (04): : 1553 - 1557
12345